Replies to post #237033 on BB's Stock Haven

[Blutribe]

BO 14172...here is the press release...ZANN Corp. Addresses Change in Trading Symbol
Thursday March 10, 12:45 pm ET


FENTON, Mich.--(BUSINESS WIRE)--March 10, 2005--ZANN Corp. (previously OTCBB:ZANN) announced that it is currently trading under the symbol ZANC (OTCBB:ZANC - News).
Effective March 10, 2005, the Company implemented a one for 350 reverse split of its authorized and outstanding shares of common stock. The number of authorized and outstanding shares of the Company's common stock following the March 10, 2005 reverse split is 11,428,572 and 3,028,861, respectively.

ZANN Corp. Reports on Antibody Development Success
Friday March 4, 9:49 am ET


FENTON, Mich.--(BUSINESS WIRE)--March 4, 2005--ZANN Corp. (OTCBB:ZANN - News) announced today that they now have initial success in developing effective specific antibodies against one major species of bacteria found in human blood. The commercial value of this achievement has significant upside potential both in medical diagnostics and gene therapy products.
According to Luther E. Lindner, MD, PhD, Chief Medical Officer, "ZANN Corp.'s scientists (formerly Pathobiotek) have been culturing and characterizing a set of bacteria that they found to be generally present in the human bloodstream. Their characterization to date has been reported at five (ASM, Pathologists and Blood) scientific/medical meetings. One species is now in continuous culture and another major species is nearly in continuous culture. As the culture system improves, their properties, particularly their ability to persist in the bloodstream, have attractive potential for their development as a platform for some types of gene therapy.

"We have been collaborating with another company for the development of our monoclonal antibodies directed against two major species of bacteria. The role of these bacteria in disease is still not entirely clear, but their continuous presence in the human bloodstream gives them the opportunity to be associated with still-unexplained disease processes. Previous small-scale studies have found an increased level of these bacteria in the active stages of several conditions, such as classical autoimmune diseases, multiple sclerosis, and chronic fatigue syndrome. The production of these monoclonal antibodies will allow development of more practical and specific quantitative testing and should help establish links with disease."

ZANN Corp. intends to establish collaborations to develop and market specific tests based on these antibodies. The market for these tests remains to be established, but at least one million Americans are diagnosed with one of the conditions where elevated levels of these bacteria have been seen. It is expected that a specific quantitative test will have value for evaluating disease activity in this population. As the testing system is developed and other studies of pathogenicity are done, it is likely that additional disease associations will be found.

ABOUT ZANN CORP.

ZANN Corp. manages our five main scalable technologies and systems - nutraceuticals, niche market vehicle sales, financial services, antibodies and gene therapy for potentially harmful bacterium while managing performance. Each technology group is a profit center measured by its contribution to overall significant growth that enables building a company with a diverse range of high quality, high value products and services for niche markets where we can excel.

For additional information please visit the corporate website at: www.zanncorp.com